Arbutus Biopharma Corp (ABUS) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 44 days, typically, give or take 20 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Tue, Nov 10, 2026before open 41 8-K
Q2 FY2026Wed, Aug 12, 2026before open 43 8-K
Q1 FY2026Wed, May 13, 2026before open 43 8-K
Q4 FY2025Mon, Mar 23, 2026before open 82 8-K
Q3 FY2025Thu, Nov 13, 2025before open 44 8-K
Q2 FY2025Wed, Aug 6, 2025before open 37 8-K
Q1 FY2025Wed, May 14, 2025before open 44 8-K
Q4 FY2024Thu, Mar 27, 2025before open 86 8-K

What they guided beta

Q2 FY2026 "EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026 Received first payment of approximately $178M from Moderna settlement in July and expects to return up to approximately $230M in capital to Arbutus shareholders Filed three international patent enforcement lawsuits against Pfizer and BioNTech related to lipid nanoparticle (LNP) technology Achieved alignment with the U.S. Food a" exhibit
Q2 FY2026 "In addition, the Company owns approximately 16% of the outstanding common equity of Genevant and anticipates the payment of a material dividend from Genevant in the third quarter of 2026." exhibit
Q2 FY2026 "Corporate Updates Arbutus expects to return capital to shareholders commencing in Q3 2026 through repurchases of up to approximately $230 million of the Company’s common shares, which repurchases may come in the form of a tender offer (including a modified “Dutch Auction” tender offer), open market purchases, accelerated share repurchases or other means." exhibit
Q1 FY2026 "Under the Company’s license with Genevant, the Company expects to receive in July 2026 an estimated $178.7 million of the Noncontingent Settlement Payment, which includes reimbursement of the Company’s litigation costs." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ABUS
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ABUS

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

ABUS earnings date badge

HTML

<a href="https://veritasdata.dev/company/ABUS/"><img src="https://veritasdata.dev/embed/ABUS.svg" alt="ABUS earnings date" width="240" height="56"></a>

Markdown

[![ABUS earnings date](https://veritasdata.dev/embed/ABUS.svg)](https://veritasdata.dev/company/ABUS/)

Script

<script async src="https://veritasdata.dev/embed/ABUS.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ABUS"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.